Aquestive Therapeutics, Inc. (AQST)Healthcare | Drug Manufacturers - Specialty & Generic | Warren, United States | NasdaqGM
4.32 USD
+0.06
(1.408%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 4.30 -0.02 (-0.020%) ⇩ (April 17, 2026, 7:20 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:33 p.m. EDT
AQST is a highly volatile stock with significant short-term risks and limited long-term growth potential. The recent price movement has been relatively stable, but the stock is trading near its 52-week low, suggesting potential for a rebound. However, the fundamental data shows negative earnings and a high overall risk, which makes it unsuitable for long-term investment. The options activity suggests a mix of bullish and bearish sentiment, but the lack of consistent dividends and weak fundamentals make it a risky proposition for most investors. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.132591 |
| AutoARIMA | 0.158245 |
| AutoETS | 0.158251 |
| MSTL | 0.176491 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 55% |
| H-stat | 1.37 |
| Ljung-Box p | 0.132 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 7.29 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.417 |
| Market Cap | 527,234,624 |
| Forward P/E | -7.45 |
| Beta | 1.53 |
| Profit Margins | -188.09% |
| Website | https://www.aquestive.com |
As of April 11, 2026, 1:33 p.m. EDT: Options activity shows mixed signals. Calls have high open interest and volatility, particularly at the 6.0 strike, suggesting some speculation on potential upside. Puts have higher open interest at the 5.0 and 3.0 strikes, indicating caution or bearish sentiment. The high IV and OI at the 6.0 strike suggest some traders are anticipating a potential move higher, while the increased put activity at lower strikes indicates concern about downside risk. Overall, the options market is showing a balanced view with both bullish and bearish positioning.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.65116274 |
| Address1 | 30 Technology Drive |
| All Time High | 20.696 |
| All Time Low | 0.618 |
| Ask | 4.41 |
| Ask Size | 10 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 997,840 |
| Average Daily Volume3 Month | 3,339,395 |
| Average Volume | 3,339,395 |
| Average Volume10Days | 997,840 |
| Beta | 1.533 |
| Bid | 4.27 |
| Bid Size | 10 |
| Board Risk | 6 |
| Book Value | -0.276 |
| City | Warren |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.32 |
| Current Ratio | 3.135 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 4.4 |
| Day Low | 4.285 |
| Display Name | Aquestive Therapeutics |
| Earnings Call Timestamp End | 1,772,715,600 |
| Earnings Call Timestamp Start | 1,772,715,600 |
| Earnings Timestamp | 1,772,658,000 |
| Earnings Timestamp End | 1,778,616,000 |
| Earnings Timestamp Start | 1,778,616,000 |
| Ebitda | -70,477,000 |
| Ebitda Margins | -1.58215 |
| Enterprise To Ebitda | -6.364 |
| Enterprise To Revenue | 10.07 |
| Enterprise Value | 448,546,624 |
| Eps Current Year | -0.46 |
| Eps Forward | -0.58 |
| Eps Trailing Twelve Months | -0.78 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.0672 |
| Fifty Day Average Change | 0.2528 |
| Fifty Day Average Change Percent | 0.062155776 |
| Fifty Two Week Change Percent | 65.11627 |
| Fifty Two Week High | 7.55 |
| Fifty Two Week High Change | -3.23 |
| Fifty Two Week High Change Percent | -0.42781457 |
| Fifty Two Week Low | 2.12 |
| Fifty Two Week Low Change | 2.2000003 |
| Fifty Two Week Low Change Percent | 1.037736 |
| Fifty Two Week Range | 2.12 - 7.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,532,525,400,000 |
| Float Shares | 111,687,086 |
| Forward Eps | -0.58 |
| Forward P E | -7.4482765 |
| Free Cashflow | -29,235,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 147 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.58345 |
| Gross Profits | 25,990,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03185 |
| Held Percent Institutions | 0.62402 |
| Implied Shares Outstanding | 122,045,049 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey. |
| Long Name | Aquestive Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 527,234,624 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_8142504 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -83,784,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 527,234,611 |
| Number Of Analyst Opinions | 9 |
| Open | 4.3 |
| Operating Cashflow | -52,432,000 |
| Operating Margins | -2.2158298 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 908 941 1900 |
| Post Market Change | -0.01999998 |
| Post Market Change Percent | -0.4629625 |
| Post Market Price | 4.3 |
| Post Market Time | 1,776,468,010 |
| Previous Close | 4.26 |
| Price Eps Current Year | -9.391305 |
| Price Hint | 4 |
| Price To Book | -15.652175 |
| Price To Sales Trailing12 Months | 11.836 |
| Profit Margins | -1.88088 |
| Quick Ratio | 2.918 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.22222 |
| Region | US |
| Regular Market Change | 0.0599999 |
| Regular Market Change Percent | 1.40845 |
| Regular Market Day High | 4.4 |
| Regular Market Day Low | 4.285 |
| Regular Market Day Range | 4.285 - 4.4 |
| Regular Market Open | 4.3 |
| Regular Market Previous Close | 4.26 |
| Regular Market Price | 4.32 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,059,817 |
| Return On Assets | -0.33918 |
| Revenue Growth | 0.097 |
| Revenue Per Share | 0.417 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 122,045,049 |
| Shares Percent Shares Out | 0.1438 |
| Shares Short | 17,555,797 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 19,954,296 |
| Short Name | Aquestive Therapeutics, Inc. |
| Short Percent Of Float | 0.1649 |
| Short Ratio | 8.52 |
| Source Interval | 15 |
| State | NJ |
| Symbol | AQST |
| Target High Price | 11.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 8.88889 |
| Target Median Price | 9.0 |
| Total Cash | 121,169,000 |
| Total Cash Per Share | 0.993 |
| Total Debt | 42,481,000 |
| Total Revenue | 44,545,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.78 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.844225 |
| Two Hundred Day Average Change | -0.52422476 |
| Two Hundred Day Average Change Percent | -0.108216435 |
| Type Disp | Equity |
| Volume | 1,059,817 |
| Website | https://www.aquestive.com |
| Zip | 7,059 |